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Abstract
Background: It is common to find a high variability in the accuracy of heart failure (HF) diagnosis in electronic
primary care medical records (EMR). Our aims were to ascertain (i) whether the prognosis of HF labelled patients
whose ejection fraction (EF) was missing in their EMR differed from those that had it registered, and (ii) the causes
contributing to the differences in the availability of EF in EMR.
Methods: Retrospective cohort analyses based on clinical records of HF and attended at 52 primary healthcare
centres of Barcelona (Spain). Information of 8376 HF patients aged > 40 years followed during five years was
analyzed.
Results: EF was available only in 8.5% of primary care medical records. Cumulate incidence for mortality and
hospitalization from 1st January 2009 to 31th December 2012 was 37.6%. The highest rate was found in patients
with missing EF (HR 1.84, 95% CI 1.68 -1.95) compared to those with preserved EF. Patients hospitalized the
previous year and those requiring home healthcare (HR 1.81, 95% Confidence Interval 1.68-1.95 and HR 1.58, 95% CI
1.46-1.71, respectively) presented a higher risk of having an adverse outcome. Older patients, those more socio-
economically disadvantaged, obese, requiring home healthcare, and taking loop diuretics were less likely to have an
EF registered.
Conclusions: EF is poorly recorded in primary care. HF patients with EF missing at medical records had the worst
prognosis. They tended to be older, socio-economically disadvantaged, and more fragile.
Keywords: Primary care, Heart failure, Echocardiography, Diagnosis
Background
It is well established that heart failure (HF) symptoms,
especially during the early stages, are not specific. This
is particularly evident in obese and elderly populations,
and in patients suffering from chronic pulmonary dis-
eases [1–3]. Up to 60% of HF patients are not properly
diagnosed, and as many as 38% who are HF registered
have not had an echocardiogram registered in their med-
ical records [4, 5]. We are unaware of the causes related
to this lack of information. Two studies have shown that
some General Practitioners did not take in account EF
to diagnose HF [6, 7]. It is, therefore, difficult to properly
estimate the prognosis and evaluate the efficacy of
evidence-based treatment in a large number of HF pa-
tients, especially since much of the data comes from
clinical trials in which the population has been strictly
selected.
Prior hospitalization as a consequence of HF has been
considered a valid criterion to confirm diagnosis. Never-
theless, it is possible that gaps exist in sharing informa-
tion between the hospital and primary care setting
which may lead to under registration of HF cases in the
primary care Electronic Medical Records (EMR).
Most HF patients, especially the oldest ones and those
with multimorbidity, are mainly managed in the primary
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care setting [8] and, especially those in terminal phases
of their disease, are not eligible to be referred to a
specialist for an echocardiography.
Regarding the validity of the diagnosis, Schultz et al.,
argued that if a physician is treating a patient as having
HF it is reasonable to consider that this patient is prop-
erly labelled HF [9].
Considering the ejection fraction (EF) as a measure to
estimate prognosis has proven controversial [10, 11] a
recent meta-analysis found lower mortality in HF
patients with preserved ejection fraction (HF-PEF) than
in those with reduced ejection fraction (HF-REF) [12]. In
addition, it has been reported that in patients with
unknown EF (i.e. unrecorded) mortality is similar to those
with HF-REF and higher in those with HF-PEF [13].
Our study is aimed at analysing the different prog-
noses of patients registered as HF in primary health-
care records, depending on whether they have HF-
REF, HF-PEF, or Possible HF (HF labelled patients
with missing ejection fraction), and, if possible, to as-
certain the causes contributing to the differences in
EF availability in the EMR.
Methods
The present study is a retrospective cohort analysis with
four year follow-up. It is based on the clinical informa-
tion included in the EMR of all HF patients labelled at
the 52 primary healthcare centres of the Institut Català
de la Salut in Barcelona (Spain).
Clinical information is centralized in the SIDIAP data-
base (Information System for the Development of Re-
search in Primary Care). This database has been shown
to be a valid source for cardiovascular disease research
[13] and is linked to the Catalan hospital discharge data-
base CMBD-AH (Conjunto Mínimo Básico de Datos de
Altas Hospitalarias) [14].
All adult patients >40 years living in Barcelona (Spain),
who were labelled HF diagnosis (International Classification
Diseases: I.50) registered in their primary EMR on Decem-
ber 31st, 2012, were included.
The registration date of the HF labelling in the EMR
was considered as the date of study inclusion. The dur-
ation of the study was from the 1st January, 2009 to 31st
December, 2012.
Prognosis was determined by hospital admission as a
consequence of HF and the global mortality that
occurred during the study period.
Event-free time was defined as the period between
diagnosis registration and the first hospital admission as
a consequence of HF, global mortality, or the last contact
with the primary care services.
Ejection Fraction: in order to be able to compare our
results with previously published studies, HF patients
were classified into three categories according to the EF
closest to the date of the inclusion: HF-REF (EF < 50%),
HF-PEF (EF > = 50%), and Possible HF (when no infor-
mation, either quantitative or qualitative, about EF was
found in the medical records) (Fig. 1).
The following potentially confounding variables at
baseline for EF effect were considered: age, gender,
hospitalization for HF the year prior to inclusion in the
study, smoking habit, cardiovascular risk factors (hyperten-
sion, diabetes, hypercholesterolemia, obesity), cardiovascu-
lar comorbidity (coronary heart disease, atrial fibrillation,
stroke, peripheral arterial disease), other comorbidities
(chronic obstructive pulmonary disease, chronic nephropa-
thy), cardiovascular drug use (antiagregants, lipid lowering
drugs, beta-blockers, angiotensin converting-enzyme inhibi-
tors or angiotensin receptor blockers, and loop diuretics).
We also recorded whether the patients required domiciliary
healthcare. Socio-economic levels were measured by the
MEDEA index which categorizes populations in quintiles,
the first one representing the least disadvantaged. This
index is based on several items (unemployment, percentage
of manual and temporary workers and persons with insuffi-
cient education overall and in young people) [15].
The whole population registered as HF in the primary
care EMR in Barcelona (Spain) was included in the ana-
lysis, resulting in a sample of 8376 HF patients. These
sample reflects the whole population labelled as HF.
Fig. 1 Classification of heart failure patients according to ejection fraction in primary care electronic medical records
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In 52 participating primary healthcare centres were
registered more than one million subjects. Such a sam-
ple size reaches 94% statistical power (estimated power
for Cox regression with Wald test; alpha = 0.05 two
sides) with a minimum of 30% events observed. It thus
ensures enough statistical power to answer the main
questions of the study.
Data are expressed as frequencies and percentages for
categorical variables, and means (standard deviation) for
continuous ones. Baseline homogeneity of variables accord-
ing to the EF was analysed. The one-way ANOVA, and
Chi-square tests were used to evaluate differences amongst
groups with different or missing EF.
Cumulate incidence of mortality, hospital admission or
a combined variable of both events during the follow-up
period was estimated for each group (HF-REF, HF-PEF,
and Possible HF).
To evaluate the differences among groups according
to the time from the inclusion date, Cox regression
models crude and adjusted were made. The Hazard
Ratio (HR) of each group with respect to the reference
was calculated and 95% confidence intervals (95%CI)
were estimated to compare the groups. The models were
compiled using the Enter Method, including clinically
relevant co-variables and those statistically associated
with the previous EF (< or equal to 50%, > 50%, or not
available). We evaluated goodness-of-fit and the Cox
model’s proportional risk assumption, as well as the in-
teractions at different levels of exposure to each drug,
using the Schoenfeld residual analysis. Furthermore, to
evaluate the factors related to the probability of having
an EF, multivariable logistic regression was performed.
For all analyses, a two-tailed p < 0.05 was considered sta-
tistically significant. IBM-SPSS PC v21 package was used
to perform statistical analysis.
Results
From 1st January, 2009 to 31st December 2012, a total
of 8376 patients labelled with HF met study criteria,.
Median follow-up to event or end of the study was 16.3
months. During the study period, 1608 (19.2%) patients
died and 2264 (27.0%) were hospitalized.
Women represented 55.9% of patients and mean age
of the population was 78.0 (SD 10.2) years.
Among the sample, 3013 patients (36%) had been ad-
mitted to hospital during the year prior to inclusion in
the study as a consequence of HF. Ejection fraction was
available only in 8.5% of the EMR.
The flow chart represents the distribution of outcomes
according to EF (Fig. 1).
By comparing the three categories according to EF, pa-
tients in the group with HF-REF were predominantly
men (67.0%), had been hospitalized as a consequence of
HF the year prior to inclusion in the study (43.8%), and
suffered more frequently from coronary heart disease
(42.7%). These patients were more often treated with
ACE inhibitors and beta-blockers (85.5 and 69.9%,
respectively).
Patients with Possible HF were older, required home
healthcare, obese, and more frequently treated with loop
diuretics. With the exception of coronary disease, no dif-
ferences were observed in the proportion of patients
with atrial fibrillation, stroke history, peripheral artery
disease, chronic pulmonary disease, and chronic renal
failure according to the EF among the three categories.
The use of ACE inhibitors and beta- blockers was very
similar in the group of HF-PEF and Possible HF. The
highest proportion of hospitalized or died patients was
in the group of Possible HF (39.1%) (Table 1).
Table 2 shows the crude and adjusted hazard ratios
for hospitalization or death. Cumulate incidence was
37.6%, and the highest rate was found in patients
with Possible HF.
The oldest patients presented 60% more risk (HR: 1.6;
CI95%:1.40-1.83) of having an adverse event than the
younger ones (≤71 years). Being hospitalized as a conse-
quence of a decompensation the year prior to inclusion
almost doubled the risk for re-hospitalization or death
(HR: 1.81; CI95%:1.68-1.95). In addition, patients requir-
ing home healthcare had 60% (HR:1.58; CI95:1.46-1.71)
more risk than the others of having an adverse event.
This risk was also higher among patients living in socio-
economically disadvantaged neighborhoods (HR:1.13;
CI95%:1.01-1.27).
Hypertension, diabetes, pulmonary and renal diseases,
and cardiovascular comorbidity were also associated
with a higher risk of having an adverse outcome. Medi-
cation for hypercholesterolemia and hypertension, how-
ever, worked as protective factors. In contrast, patients
taking loop diuretics had a higher rate of adverse
outcomes.
Patients hospitalized the year before and without an
EF registered in the EMR presented an HR of 4.99, and
a 95% Confidence Interval 3.67 to 6.78, for being hospi-
talized or dying during follow-up.
The adjusted analysis to identify the causes related to
the higher probability of missing an EF in the medical
records showed that among patients who were elderly,
more socio-economically disadvantaged, obese, requiring
home healthcare, and taking loop diuretics it was less
common to have one registered (Table 3).
Discussion
Our study found that patients labelled with HF who did
not have an EF registered in their primary care EMR
presented the highest rates of death and hospital re-
admissions with respect to those who did. Patients hos-
pitalized as a consequence of HF decompensation the
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year prior to study inclusion presented a higher prob-
ability of having an adverse outcome during follow- up.
The use of administrative databases could be a limita-
tion to properly answer some research questions. The
difficulty of having an accurate HF diagnosis registered
is well known. Although it has been reported that most
HF diagnoses registered in EMR correspond to authentic
cases, about one-quarter are not recorded [16].
On the other hand, the use of a large primary care
database allows us to have information about the whole
population and confers a high external validity. This val-
idity has been previously analyzed and found good for
the study of cardiovascular diseases [13]. Although
MEDEA deprivation index is not an individual measure
but an ecological one, it is useful as a proxy to deter-
mine socioeconomic position of the population living in
a geographical area.
The MAGGIC study had already reported higher mor-
tality in Possible HF patients, but their proportion of
missing EF was lower in our study and some questions
were not completely answered, such as socioeconomic
position and setting of care (ambulatory or home health-
care, and). In this way we found that patients requiring
home care and those in more disadvantaged economic
position had a higher probability of not having a EF
registered at their EMR.
Table 1 Characteristics, clinical profile, and treatment according to the ejection fraction of heart failure patients
EF >50
n=418
EF <=50
n=297
No EF
n=7661
EF>50 versus
No EF
EF < =50 versus
No EF
n % N % n % p value p value
Gender (women) 253 60,5 98 33,0 4331 56,5 0,109 <0.001
Age (Mean,SD) 77.1 (9.5) 74.2 (11.5) 78.3 (10.2) 0.053 <0.001
Socioeconomic deprivation index
1 (less disadvantaged) 98 23.4 60 20.2 1486 19.4
2 126 30.1 97 32.6 1377 17.9
3 102 24.4 53 17.8 1533 20.0
4 60 14.3 48 16.1 1544 20.1
5 (more disadvantaged) 29 6.9 36 12.1 1586 20.7 <0.001 <0.001
Previous hospitalization for heart failure 91 21.8 130 43.8 2792 36.4 <0.001 0,010
Patients requiring home care 64 15.3 54 18.1 2124 27.7 <0.001 <0.001
Cardiovascular risk factors
Hypertension 328 78.4 214 72.0 5823 76.0 0,250 0,118
Diabetes 129 30.8 108 36.3 2528 33.0 0,365 0,227
Hypercholesterolemia 145 34.6 97 32.6 2241 29.2 0,018 0,206
Obesity 71 16.9 42 14.1 1742 22.7 0,006 <0.001
Smoking habit 26 6.2 33 11.1 619 8.0 0,380 <0.001
Cardiovascular disease
Coronary heart disease 94 22.4 127 42.7 2009 26.2 0,090 0,000
Atrial fibrillation 150 35.8 98 33.0 2794 36.4 0,809 0,222
Stroke 37 8.8 30 10.1 770 10.0 0,426 0,978
Peripheral artery disease 26 6.2 24 8.0 463 6.0 0,883 0,151
COPD 65 15.5 49 16.50 1240 16.19 0,731 0,886
Chronic renal failure 83 19.8 53 17.85 1397 18.24 0,404 0,864
Drug therapy
ACE inhibitor or ARB 305 73.0 254 85.5 5736 74.9 0,382 <0.001
Beta-blocker 212 50.7 205 69.0 3729 48.7 0,416 <0.001
Loop diuretics 246 58.8 212 71.38 5889 76.8 <0.001 0,028
Outcomes
Hospitalization 50 11,96 57 19,1 2157 28,1 0,000 0,001
Mortality 30 7,18 33 11,1 1545 20,1 0,000 0,000
EF Ejection Fraction, SD Standard deviation, COPD Chronic obstructive pulmonary disease, ACE angiotensin converting enzyme, ARB Angiotensin Receptor Blocker
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Table 2 Cumulate incidence and hazard ratio, crude and adjusted, for hospitalization or death, with respect to socio demographic
characteristics, clinical profile, and treatment received for heart failure
Cumulate Incidence Crude Hazard Ratio Adjusted Hazard Ratio
Rate (%) 95% Confidence interval HR 95% Confidence interval HR 95% Confidence interval
Goblal incidence 37.6 36.5-38.7
Ejection Fraction
Ejection Fraction>50 17.0 13.3-20.7 1 1
Ejection Fraction <=50 27.3 22.1-32.4 1.81 1.31-2.49 1.36 0.99-1.88
Missing Ejection Fraction 39.1 38.0-40.2 2.33 1.84-2.95 1.84 1.45-2.33
Previous hospitalization for heart failure 51.3 49.5-53.1 2.18 2.03-2.34 1.81 1.68-1.95
Gender (Male) 39.8 38.2-41.4 1.15 1.07-1.23 1.24 1.14-1.34
Age (quintiles)
(<=71 years; reference 29.0 26.8-31.1 1 1
72 - 78 33.3 31.2-35.5 1.14 1.02-1.28 1.03 0.91-1.16
79 - 82 38.1 35.6-40.5 1.43 1.27-1.61 1.21 1.07-1.37
3 - 86 41.1 38.5-43.6 1.62 1.44-1.82 1.30 1.14-1.48
>=87 48.8 46.2-51.3 2.17 1.94-2.43 1.60 1.40-1.83
Socio economic deprivation index
1 (less disadvantaged) 33.5 31.1-35.8 1 1
2 36.7 34.3-39.1 1.08 0.96-1.21 1.10 0.98-1.24
3 37.3 34.9-39.6 1.06 0.95-1.19 1.01 0.90-1.13
4 38.6 36.2-41.0 1.11 0.99-1.25 1.03 0.92-1.16
5 (more disadvantaged) 42.8 40.4-45.3 1.28 1.14-1.43 1.13 1.01-1.27
Patients requiring home care 57.0 55.0-59.1 2.13 1.98-2.29 1.58 1.46-1.71
Cardiovascular risk factors
Hypertension 38.3 37.1-39.5 1.13 1.04-1.22 1.08 0.99-1.19
Diabetes 41.6 39.7-43.5 1.25 1.16-1.34 1.17 1.08-1.26
Hypercholesterolemia 34.5 32.6-36.4 0.90 0.83-0.97 0.94 0.86-1.02
Obesity 37.7 35.5-40.0 0.99 0.91-1.08 1.00 0.92-1.10
Smoking habit 39.2 35.5-43.0 0.98 0.87-1.11 1.04 0.91-1.19
Cardiovascular diseases
Coronary heart disease 41.5 39.4-43.6 1.21 1.12-1.31 1.11 1.02-1.21
Atrial fibrillation 42.4 40.6-44.2 1.31 1.22-1.41 1.05 0.96-1.15
Stroke 44.7 41.2-48.1 1.41 1.26-1.57 1.15 1.03-1.29
Peripheral artery disease 45.4 41.0-49.8 1.45 1.27-1.66 1.11 0.97-1.28
Other comorbidities
Chronic obstructive pulmonary disease 45.1 42.3-47.8 1.39 1.28-1.52 1.25 1.14-1.37
Chronic renal failure 44.8 42.3-47.4 1.47 1.35-1.60 1.18 1.08-1.29
Drug therapy
ACE inhibitor or ARB* 37.3 36.1-38.5 0.91 0.84-0.99 0.85 0.78-0.93
Beta-blocker 37.9 35.3-40.5 1.00 0.91-1.09 1.03 0.94-1.14
Loop diuretics 42.5 41.3-43.8 2.27 2.05-2.51 1.64 1.48-1.82
Statins 35.1 33.6-36.6 0.87 0.81-0.94 0.85 0.79-0.93
aACE angiotensin converting enzyme, ARB Angiotensin Receptor Blocker
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On the other hand, Possible HF patients had up to
50% more probability of having adverse outcomes than
those with HF-REF, and the risk doubled with respect to
HF-PEF patients [13].
We have identified several factors which could help
explain these findings. Firstly, patients who lacked infor-
mation about EF were older, as has been reported by
other authors in patients attended for acute heart failure
at hospital emergency rooms [17]. In our population, the
probability for the oldest patients of having an EF
recorded in their EMR was less than 50% with respect to
the others.
Socio-economic inequality regarding access to special-
ized care in newly diagnosed HF patients, and a lower
probability of undergoing invasive cardiac procedures
for the less disadvantaged populations, have been previ-
ously described [18, 19]. Nevertheless, most evidence
comes from countries with differing healthcare systems
where accessibility could vary. In contrast, the Spanish
National Health System provides healthcare universal
and free. Previous studies performed by our group did
not find any inequality regarding therapeutic manage-
ment in populations suffering from coronary heart
disease [20] or at high cardiovascular risk [21, 22].
We, cannot, therefore, satisfactorily account for the
fact that the more socio- economically deprived patients
showed a lower probability of having an echocardiog-
raphy performed.
Due to their deteriorated health, patients needing
home care are not usually candidates to be referred to
undergo tests and explorations, including EF measures.
As a consequence, the probability of having an echocar-
diography is lower than in those with a better life
expectancy. Home healthcare is generally oriented
towards achieving a better quality of life rather than
actually lengthening it. In addition, patients needing this
service usually have a very limited quality of life and the
hypothetical availability of their EF figures would
probably not result in treatment changes. A recent
experience in united Kingdom showed that a program
of basic cardiac scans (‘Quick scans’) performed in
highest risk population could reduce the demand of
echocardiography and optimize the detection of struc-
tural disease [23].
In agreement with other authors, we found that
previous history of HF hospitalization, especially in
the previous year, is a powerful predictor for having
recurrent events [24–26].
In addition, and again concurring with other publica-
tions, we observed that the use of loop diuretics was asso-
ciated with a higher risk of mortality and hospitalization
in HF patients. It has been argued that this effect occurs
especially when doses are high and glomerular filtration
declines [27].
Conclusions
EF is poorly recorded in primary care. HF patients with
EF missing at medical records had the worst prognosis
with regard to hospitalisation and survival. They tended
to be older, socio-economically disadvantaged, and more
fragile.
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